SUNNYVALE, Calif. - BioCardia, Inc. (NASDAQ:BCDA), a biotech company specializing in cardiovascular cell therapies, has entered into a partnership with StemCardia, Inc. to develop a new stem cell treatment for heart failure. The collaboration, announced today, will utilize BioCardia's Helix biotherapeutic delivery system for the administration of StemCardia's cardiac muscle cells in clinical studies aimed at FDA approval.
The partnership comes as heart failure remains a leading cause of mortality worldwide with limited effective treatment options. BioCardia's Helix system is known for its safe and minimally invasive method of delivering cellular medicines directly into the heart, a technique that has been successfully employed in large animal models of heart failure.
StemCardia's investigational pluripotent stem cell product candidate is designed to re-muscularize and restore function to the failing heart. The company's approach involves the transplantation of off-the-shelf cardiac muscle cells, which could potentially offer a curative solution to patients with heart failure.
BioCardia's CEO, Peter Altman, PhD, expressed optimism about the partnership's potential to enhance treatment options for heart failure patients and provide financial benefits for investors through revenue sharing, should the collaboration lead to successful therapeutic development.
The press release also highlights the forward-looking nature of the statements regarding the potential benefits of the therapy and partnership, future revenues, and clinical trials. It notes the inherent uncertainties that accompany the development of new products and technologies, regulatory approvals, and the need to raise additional funding.
Both companies have emphasized their commitment to advancing treatments for heart failure, bringing together expertise in heart regeneration, cell manufacturing, and genetic medicine. The partnership is based on a press release statement and aims to progress towards FDA approval and subsequent clinical development phases.
BioCardia and StemCardia's collaboration represents a strategic effort to address a significant unmet medical need, with the potential to transform the therapeutic landscape for heart failure patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.